The following transactions have been completed by Corvus and its Management Team
Conduit Pharmaceuticals
Corvus is the founding and majority shareholder of Conduit Pharmaceuticals, a disease agnostic life science company providing an efficient model for compound development. Formed in 2019, Conduit is a departure from the traditional big pharma/biotech business model whereby, typically companies shepherd their assets through regulatory approval, Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Conduit successfully completed a business combination with Murphy Canyon Acquisition Corp. (Nasdaq: MURF) in September 2023 for a proforma enterprise value of approximately $720 MM.
(Nasdaq: CDT)